Trials / Terminated
TerminatedNCT04303845
Erenumab For Treatment of Hemicrania Continua
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 66 Years
- Healthy volunteers
- Not accepted
Summary
This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erenumab | 140 mg of erenumab via subcutaneous injection |
Timeline
- Start date
- 2021-08-04
- Primary completion
- 2022-04-06
- Completion
- 2022-04-06
- First posted
- 2020-03-11
- Last updated
- 2023-02-17
- Results posted
- 2023-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04303845. Inclusion in this directory is not an endorsement.